XBiotech Inc.
XBIT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626878
No open-market purchases or sales by XBiotech Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $4.56M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 36
- 13F valueReported value at the end of Q2 2026
- $4.56M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding XBIT, Q2 2026
No superinvestor reported holding XBIT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by XBiotech Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2024 (view filing) | Jan 3 | 2 days | Simard JohnChief Executive Officer | PPurchaseCommon Shares or Preferred Shares | +2.47M | $10,000,000.00 | +$24.7T | –3.84M after | DerivativePrice outlier |
| Feb 15, 2022 (view filing) | Oct 15-18, 2021 | 123 daysLate | Simard JohnChief Executive Officer | SSale | −50.0K | $13.16 | −$657.8K | −1.3%3.82M after | 2 lots |
| Oct 15, 2021 (view filing) | Oct 7-14 | 8 daysLate | Simard JohnChief Executive Officer | SSale | −89.3K | $12.67 | −$1.13M | −2.3%3.87M after | 4 lots |
| Oct 6, 2021 (view filing) | Oct 4-6 | 2 days | Simard JohnChief Executive Officer | SSale | −48.6K | $12.84 | −$624.0K | −1.2%3.96M after | 3 lots |
| Oct 1, 2021 (view filing) | Sep 28-Oct 1 | 3 daysLate | Simard JohnChief Executive Officer | SSale | −60.9K | $13.34 | −$812.2K | −1.5%4.01M after | 4 lots |
| Sep 28, 2021 (view filing) | Sep 23-27 | 5 daysLate | Simard JohnChief Executive Officer | SSale | −51.2K | $14.71 | −$753.3K | −1.2%4.07M after | 3 lots |
| Sep 22, 2021 (view filing) | Sep 20-22 | 2 days | Simard JohnChief Executive Officer | SSale | −50.0K | $15.15 | −$757.6K | −1.2%4.12M after | 3 lots |
| Jul 19, 2021 (view filing) | Jul 14 | 5 daysLate | Simard JohnChief Executive Officer | SSale | −50.0K | $18.15 | −$907.5K | −1.2%4.17M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in XBiotech Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 321,146 | $738.6K | 0.00% | +28,042+9.6% | Added |
| Geode Capital Management, LLC | 214,116 | $492.8K | 0.00% | −16,904−7.3% | Reduced |
| Vanguard Capital Management LLC | 200,182 | $460.4K | 0.00% | −789−0.4% | Reduced |
| RBF Capital, LLC | 198,501 | $456.6K | 0.02% | 00.0% | Unchanged |
| Morgan Stanley | 147,880 | $340.1K | 0.00% | −17,674−10.7% | Reduced |
| Bridgeway Capital Management, LLC | 98,447 | $226.4K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 92,365 | $212.4K | 0.00% | +789+0.9% | Added |
| Millennium Management LLC | 79,330 | $182.5K | 0.00% | −26,210−24.8% | Reduced |
| State Street Corp | 73,006 | $167.9K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 66,258 | $152.4K | 0.00% | −9,829−12.9% | Reduced |